Moderna's clinical details for Phase 1 of the New Crown Vaccine were published.

In this trial, 45 healthy adult subjects aged 18-55 were given two doses of mRNA-1273 at different doses (25, 100, 250 s g) at intervals of 28 days.
results as of the 57th day after vaccination showed that mRNA-1273 induced a rapid and intense immune response to the new coronavirus.
led the study by the National Institutes of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).
immunogenic response mRNA-1273 induces all subjects to produce antibodies that bind to the full-length new coronavirus sting protein on the 15th day after the first inoculation.
in the 57th day after two vaccinations, the geometric average titer exceeded the geometric average titer of the recovery period serum obtained from 38 patients diagnosed with COVID-19.
researchers evaluated neutralizing antibody activity using two different tests, one was the neutralizing test for the decay of the new coronavirus (PRNT) and the other with the pseudovirus neutralizing test (PsVNA).
no subjects detected prnt or PsVNA reactions prior to vaccination. After two
, mRNA-1273 caused a high level of neutralizing antibody immune response.
43rd day, neutralizing anti-antibody activity (PRNT) against neo-coronavirus was observed in all subjects evaluated.
at a dose of 100 ?g, the geometric average titer level was 4.1 times the observed level in the serum (n-3) of the patient in the patient of the reference rehabilitation.
second inoculation, PsVNA neutralizing antibody titer in all subjects in the dose line was detected. the geometric average titer for the 57th day of the
at a dose of 100 ?g was 2.1 times higher than the titer observed in the recovery serum (n?38).
The researchers also assessed the immune response of T-cells at doses of 25 ?g and 100 ?g ( pic.com.au) (Photo Source: References)
second inoculation, mRNA-1273 caused the response of Th1-biased CD4-positive T-cells, while the response of Th2-biased CD4-positive T-cells did not significantly increase.
Security Features The mRNA-1273 is safe and well tolerated in terms of safety until the 57th day without reporting a serious adverse event.
adverse events (AE) are usually mild to moderate in severity and are one-time events.
the second inoculation, 7 of the 13 subjects in the 25-g group (54%), all 15 subjects in the 100-g group and all 14 subjects in the 250?g group had systemic adverse events.
the second dose of 100 ?g, the most commonly reported systemic adverse events were fatigue (80%), chills (80%), headaches (60%) and myalgia (53%), with mild or moderate severity. The most common local adverse event in the
100?g dose group was injection site pain (100%), with mild or moderate severity.
"These positive Phase 1 data are encouraging and represent an important step forward in the clinical development of our candidate vaccine mRNA-1273.
moderna team will continue this month to focus on launching our Phase 3 study and, if successful, will submit a bioproduct licensing application," said Mr. St?phane Bancel, Chief Executive Officer of Moderna, "We are committed to advancing the clinical development of mRNA-1273 as quickly and safely as possible, while investing in expanding production to help address this global health emergency."
" Moderna expects Phase 3 clinical trials to begin on July 27 with a dose of 100 ?g.
expects the trial to recruit 30,000 participants.
References: Moderna Announcs Publication in The New England Medicine Medicine Sing of The New England Medicine s Of Interim of The Results From Phase 1 Study of Its MRNA Vaccine Against COVID-19 (mRNA-1273). Retrieved D. July 14, 2020, from .2. Jackson et al., (2020). An mRNA Vaccine against SARS-CoV-2 - Preliminary Report. NEJM, DOI: 10.1056/NEJMoa2022483 Original title: Neutralizing antibody titer exceeds in rehabilitated patients, Moderna New Crown Vaccine Phase 1 Clinical Details Published.